Holen Sie sich die Stockscreener-App
287.41
0.53%
-1.65
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$289.06
Offen:
$288.25
24-Stunden-Volumen:
273.96K
Relative Volume:
0.31
Marktkapitalisierung:
$42.07B
Einnahmen:
$5.15B
Nettoeinkommen (Verlust:
$1.40B
KGV:
30.22
EPS:
9.51
Netto-Cashflow:
$1.65B
1W Leistung:
+0.98%
1M Leistung:
+10.13%
6M Leistung:
+24.10%
1J Leistung:
+28.19%
1-Tages-Spanne:
$286.31
$288.65
1-Wochen-Bereich:
$283.15
$290.30
52-Wochen-Spanne:
$199.92
$293.08
Resmed Inc Stock (RMD) Company Profile
Firmenname
Resmed Inc
Sektor
Telefon
(858) 746-2400
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Vergleichen Sie RMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
287.34 | 41.89B | 5.15B | 1.40B | 1.65B | 9.51 |
|
ISRG
Intuitive Surgical Inc
|
475.00 | 172.53B | 9.15B | 2.63B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
198.22 | 55.89B | 21.39B | 1.61B | 2.55B | 5.56 |
|
ALC
Alcon Inc
|
79.16 | 43.59B | 9.93B | 1.12B | 1.43B | 2.26 |
|
WST
West Pharmaceutical Services Inc
|
243.21 | 17.48B | 2.96B | 487.70M | 344.00M | 6.68 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-01-16 | Eingeleitet | Goldman | Buy |
| 2025-01-10 | Eingeleitet | Piper Sandler | Neutral |
| 2024-12-13 | Eingeleitet | Stifel | Hold |
| 2024-09-24 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-09-18 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Herabstufung | Needham | Buy → Hold |
| 2024-06-25 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Hochstufung | Needham | Hold → Buy |
| 2023-09-05 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Eingeleitet | UBS | Buy |
| 2023-04-14 | Eingeleitet | Mizuho | Buy |
| 2023-01-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-20 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-09-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-08-15 | Herabstufung | CLSA | Buy → Outperform |
| 2022-08-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-01-31 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-28 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Hochstufung | CLSA | Outperform → Buy |
| 2022-01-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-10-22 | Hochstufung | CLSA | Underperform → Outperform |
| 2021-08-02 | Herabstufung | CLSA | Outperform → Sell |
| 2021-08-02 | Herabstufung | Needham | Buy → Hold |
| 2021-07-28 | Hochstufung | Jefferies | Underperform → Hold |
| 2021-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2021-06-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-06-22 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-06-22 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-06-21 | Bestätigt | Needham | Buy |
| 2021-06-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Hochstufung | CLSA | Sell → Outperform |
| 2021-05-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-16 | Hochstufung | Needham | Hold → Buy |
| 2020-11-02 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Eingeleitet | CLSA | Underperform |
| 2020-01-31 | Herabstufung | UBS | Buy → Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-22 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Hochstufung | UBS | Neutral → Buy |
| 2019-07-16 | Herabstufung | UBS | Buy → Neutral |
| 2019-05-06 | Hochstufung | UBS | Neutral → Buy |
| 2019-04-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Eingeleitet | Goldman | Buy |
Alle ansehen
Resmed Inc Aktie (RMD) Neueste Nachrichten
ResMed Updates Dividend Exchange Rate for ASX CDI Holders - MSN
Resmed names new board director - HME News
Stock Analysis | ResMed OutlookTechnical Weakness Weighs Despite Strong Fundamentals - AInvest
ResMed up on bullish analyst notes after solid quarter - MSN
Resmed Director Makes a Significant Stock Sale! - TipRanks
Buy ResMed and this ASX stock for 10%+ returns - MSN
Resmed director Hernandez sells $739k in stock - Investing.com
Resmed Inc Announces Proposed Sale of Securities - TipRanks
Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio - Koreabizwire
Resmed Elects Nicole Mowad-Nassar to Board of Directors, Announces Retirement of Rich Sulpizio - Quiver Quantitative
Resmed announces election of Nicole Mowad-Nassar to board, upcoming retirement of Rich Sulpizio - MarketScreener
Resmed, Inc. - Via Ritzau
CICC Adjusts Price Target on ResMed to $325 From $295, Maintains Outperform Rating - MarketScreener
Is ResMed Inc. forming higher highs and higher lowsIndex Update & Target Return Focused Stock Picks - thegnnews.com
Why ResMed Inc. stock attracts strong analyst attentionWeekly Risk Report & Growth Focused Investment Plans - thegnnews.com
Are Resmed CDI (ASX:RMD) shares good value in 2025? - Rask Media
What’s the analyst consensus on ResMed Inc.July 2025 Trade Ideas & Verified Technical Signals - newsyoung.net
ResMed Gains 0.06% as $290M Volume Ranks 357th Mixed Institutional and Analyst Signals Fuel Market Uncertainty - AInvest
22% Of This ResMed Insider's Holdings Were Sold - 富途牛牛
ResMed Shares Dip 1.23% as Daily Volume Ranks 381st Amid Market Volatility - AInvest
ResMed’s (RMD) Dividend Hike and Buybacks Could Be a Game Changer for Investor Sentiment - simplywall.st
ResMed Inc. Price Targets Raised After Rebound2025 Major Catalysts & Safe Entry Momentum Tips - beatles.ru
ResMed Inc.’s Price Action Aligns with Quant SignalsJuly 2025 Opening Moves & AI Driven Price Forecasts - sundaytimes.kr
Sector Leaders Rotate Capital Into ResMed Inc.Portfolio Risk Report & Accurate Entry/Exit Alerts - 선데이타임즈
Why ResMed (RMD) is a Top Momentum Stock for the Long-Term - Yahoo Finance
The Top 5 Analyst Questions From ResMed’s Q2 Earnings Call - Yahoo Finance
Can ResMed Inc. disrupt its industryLow Risk High Return Picks - thegnnews.com
Ex-Dividend Reminder: WEC Energy Group, UNITIL and ResMed - Nasdaq
Are Bears Losing Grip on ResMed Inc.Entry Zone Strategy for Consistent Profit Shared - beatles.ru
Why ResMed (RMD) is a Top Growth Stock for the Long-Term - sharewise.com
ResMed Rises to 432nd in Market Activity Amid 13.1% Earnings Growth Outlook and $0.24 Billion Volume - AInvest
Here's How Much You'd Have If You Invested $1000 in ResMed a Decade Ago - MSN
ResMed Insider Sold Shares Worth $2,238,379, According to a Recent SEC Filing - MarketScreener
Resmed Earnings Up 10% in FY2025 - San Diego Business Journal
ResMed Full Year 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Is ResMed's (RMD) Dividend Hike and Leadership Change Shaping Its Capital Allocation Strategy? - simplywall.st
Dividend Information on ResMed: Essential Details Before the Ex-Dividend Date on Aug 14, 2025 - AInvest
ResMed: Accelerating Global Expansion With Strong Growth in Europe & China! - Smartkarma
ResMed’s 419th High-Volume Rank Drives 166.71% Gains as Liquidity-Driven Strategy Surpasses Benchmark - AInvest
RESMED INC SEC 10-K Report - TradingView
ResMed CEO Sells Shares - MarketScreener
ResMed Inc. Reports Change in Beneficial Ownership - TipRanks
ResMed CFO Adjusts Stock Holdings in Routine Transaction - TipRanks
ResMed Ranks 453rd in $260M Volume as Institutional Buys and Earnings Beat Fuel Analyst Price Hikes - AInvest
Macro Intelligence: ResMed breathes easy with FY2025 financial growth - ig.com
ResMed Stock Slides on 39.59% Volume Drop to $280M Ranks 425th as Analysts Hike Targets to $290-$325 Amid Strong Earnings and Dividend Boost - AInvest
ResMed is an ASX share market success story that deserves your attention - MSN
Morgans Maintains Buy Rating for Resmed Inc with Price Target of A$47.86 - AInvest
Resmed Inc Reports Increase in CHESS Depositary Interests - TipRanks
ResMed Inc Announces Proposed Sale of Common Shares - MSN
Finanzdaten der Resmed Inc-Aktie (RMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):